Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction

Nature Medicine

Volumn 3, Issue 7, 1997, Pages 738-743

  Kang, Sang Mo ^a   Schneider, Darren B ^a   Lin, Zhonghua ^a   Hanahan, Douglas ^b   Dichek, David A ^a   Stock, Peter G ^a   Baekkeskov, Steinunn ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; TARGET CELL;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD95; B-LYMPHOCYTES; CELL TRANSPLANTATION; DIABETES MELLITUS, EXPERIMENTAL; FAS LIGAND PROTEIN; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT REJECTION; ISLETS OF LANGERHANS; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; NEUTROPHILS; T-LYMPHOCYTES; TRANSFORMATION, GENETIC; TRANSPLANTATION IMMUNOLOGY;

MURINAE; MUS MUSCULUS;

EID: 0030842535     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0797-738     Document Type: Article

References (44)

1. Nagata, S. Fas and Fas ligand: A death factor and its receptor. Adv. Immunol. 57, 129-144 (1994).
2. Krammer, P.H. et al. The role of APO-1-mediated apoptosis in the immune system. Immun. Rev. 142, 175-191 (1994).
3. Nagata, S. & Golstein, P. The Fas death factor. Science 267, 1449-1456 (1995).
4. Nagata, S. Fas ligand and immune evasion. Nature Med. 2, 1306-1307 (1996).
5. Fisher, G.H. et al. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935-946 (1995).
6. Rieux-Laucat, F. et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1349 (1995).
7. Nagata, S. & Suda, T. Fas and Fas ligand: lpr and gld mutations. Immun. Today 16, 39-43 (1995).
8. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632 (1995).
9. Griffith, T.S., Brunner, T., Fletcher, S.M., Green, D.R. & Ferguson, T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192 (1995).
10. Strand, S. et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?. Nature Med. 2, 1361-1366 (1996).
11. Hahne, M. et al. Melanoma cell expression of Fas (Apo-1/Cd95) ligand - implications for tumor immune escape. Science 274, 1363-1366 (1996).
12. Lau, H.T., Yu, M., Fontana, A. & Stoeckert, C.J., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109-112 (1996).
13. Hesse, U.J., Sutherland, D.E., Gores, P.F., Sitges-Serra, A. & Najarian, J.S. Comparison of splenic and renal subcapsular islet autografting in dogs. Transplantation 41, 271-274 (1986).
14. Sutherland, D.E. Pancreas and islet transplantation. I. Experimental studies. Diabetologia 20, 161-185 (1981).
15. Becker, T.C., BeltrandelRio, H., Noel, R.J., lohnson, J.H. & Newgard, C.B. Overexpression of hexokinase I in isolated islets of Langerhans via recombinant adenovirus. J. Biol. Chem. 269, 21234-21238 (1994).
16. Csete, M.E. et al. Efficient gene transfer to pancreatic islets mediated by adenoviral vectors. Transplantation 59, 263-268 (1995).
17. Takahashi, T. et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand. Cell 76, 969-976 (1994).
18. Hansen, W.A. et al. Supravital dithizone staining in the isolation of human and rat pancreatic islets. Diabetes Res. 10, 53-57 (1989).
19. Shiroki, R. et al. Human peripheral blood lymphocyte reconstituted severe combined immunodeficient (hu-PBL-SCID) mice: A model for human islet allograft rejection. Transplantation 57, 1555-1562 (1994).
20. Yamada, K. et al. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 39, 1306-1312 (1996).
21. Chervonsky, A. et al. The role of Fas in autoimmune diabetes. Cell 89, 17-24 (1997).
22. Adachi, M., Watanabe-Fukunaga, R. & Nagata, S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc. Natl. Acad. Sci. USA 90, 1756-1760 (1993).
23. Adachi, M. et al. Targeted mutation in the fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nature Genet. 11, 294-300 (1995).
24. Moloney, W.C., McPherson, K. & Fliegelman, L. Esterase activity in leukocytes demonstrated by the use of naphthol AS-D-chloroacetate substrate. J. Histochem. Cytochem. 8, 200-207 (1960).
25. Jolicoeur, C., Hanahan, D. & Smith, K.M. T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc. Natl. Acad. Sci. USA 91, 6707-6711 (1994).
26. Efrat, S. Sexual dimorphism of pancreatic beta-cell degeneration in transgenic mice expressing an insulin-ras hybrid gene. Endocrinology 128, 897-901 (1991).
27. Lo, D. et al. Diabetes and tolerance in transgenic mice expressing class II MHC molecules in pancreatic beta cells. Cell 53, 159-168 (1988).
28. Sarvetnick, N., Liggitt, D., Pitts, S.L., Hansen, S.E. & Stewart, T.A. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell 52, 773-782 (1988).
29. Seino, K.-I., Kayagaki, N., Okumura, K. & Yagita, H. Antitumor effect of locally produced CD95 ligand. Nature Med. 3, 165-170 (1997).
30. Abreu-Martin, M.T., Vidrich, A., Lynch, D.H. & Targan, S.R. Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J. Immunol. 155, 4147-4154 (1995).
31. Sekine, C. et al. Fas-mediated stimulation induces II-8 secretion by rheumatoid arthritis synoviocytes independently of Cpp32-mediated apoptosis. Biochem. Biophys. Res. Commun. 228, 14-20 (1996).
32. Baggiolini, M. & Clark-Lewis, I. Interleukin-8, a chemotactic and inflammatory cytokine. FEBS Lett. 307, 97-101 (1992).
33. Cacalano, G. et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 265, 682-684 (1994).
34. Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135 (1995).
35. Mariani, S.M., Matiba, B., Baumler, C. & Krammer, P.H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25, 2303-2307 (1995).
36. Kayagaki, N. et al. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182, 1777-1783 (1995).
37. Iwai, K. et al. Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 84, 1201-1208 (1994).
38. Liles, W.C., Kiener, P.A., Ledbetter, J.A., Aruffo, A. & Klebanoff, S.J. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184, 429-440 (1996).
39. Liles, W.C. & Klebanoff, S.J. Regulation of apoptosis in neutrophils - Fas track to death? J. Immunol. 155, 3289-3291 (1995).
40. Allison, J., Georgiou, H.M., Strasser, A., & Vaux, D. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration, but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA (in the press).
41. Ginsberg, H.S. et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. USA 86, 3823-3827 (1989).
42. Dong, G., Schulick, A.H., DeYoung, M.B. & Dichek, D.A. Identification of a cis-acting sequence in the human plasminogen activator inhibitor type-1 gene that mediates transforming growth factor-beta1 responsiveness in endothelium in vivo. J. Biol. Chem. 271, 29969-29977 (1996).
43. Graham, F.L. & Prevec, L. Methods in Molecular Biology. 109-128 (Humana Press, Clifton, NJ, 1991).
44. 2-Microglobulin gene disruption prolongs murine islet allograft survival in NOD mice. Trans. Proc. 26, 752 (1994).